ESLA — Estrella Immunopharma Inc Com
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.07 | — | -0.07 | -0.07 | 1 | — |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.25 | — | -0.25 | -0.25 | 1 | — |
| Dec 2027 | -0.32 | — | -0.32 | -0.32 | 1 | — |
| Dec 2028 | -0.31 | — | -0.31 | -0.31 | 1 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 16 SEC-registered investment managers reported holding ESLA (Estrella Immunopharma Inc Com) in their latest 13F filings, with a combined reported value of $2.11M across 4.51M shares. That is -6.3% by share count (-297.01K shares) versus the previous quarter, while reported value moved -57.9%. Ownership is concentrated: the five largest holders account for 97.0% of reported value and the top ten for 99.8%.
Compared with the prior quarter, 2 opened new positions, 3 added to existing stakes, 4 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of Estrella Immunopharma Inc Com (ESLA) include ARMISTICE CAPITAL, LLC, Vanguard Group, Wells Fargo & Co, ranked by reported 13F value among the 32 institutional holders on this page.
ESLA is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 16 | 4.51M | $2.11M | -6.2% |
| Q2 2026 | 15 | 4.89M | $5.09M | -2.3% |
| Q1 2026 | 16 | 5.18M | $5.49M | +0.6% |
| Q4 2025 | 15 | 999.61K | $1.56M | +25.9% |
| Q3 2025 | 11 | 693.19K | $821.32K | +18.4% |
| Q2 2025 | 9 | 584.82K | $511.55K | +0.8% |
| Q1 2025 | 9 | 563.14K | $522.10K | +103.6% |
| Q4 2024 | 9 | 242.28K | $281.11K | +54.4% |
Over the 8 quarters shown, institutional share counts increased 1762% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q1 2025 (+103.6%).
Top Institutional Holders (Q3 2026) — 16 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 3.67M | $1.71M | 0.02% | Reduce | |
| 416.85K | $194.67K | 0.00% | Hold | |
| 141.14K | $65.87K | 0.00% | Hold | |
| 94.40K | $44.08K | 0.00% | Add | |
| 52.87K | $24.67K | 0.00% | Add | |
| 43.25K | $20.19K | 0.00% | Hold | |
| 34.86K | $16.27K | 0.00% | Hold | |
| 27.55K | $12.86K | 0.00% | New | |
| 14.70K | $6.86K | 0.00% | Reduce | |
| 6.50K | $3.03K | 0.00% | Add | |
| 5.91K | $2.76K | 0.00% | New | |
| 1.36K | $633 | 0.00% | Reduce | |
| 1.09K | $509 | 0.00% | Hold | |
| 468 | $218 | 0.00% | Hold | |
| 2 | $1 | 0.00% | Hold | |
| 2 | $1 | 0.00% | Reduce |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 15 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 3.98M | $4.13M | 0.05% | Reduce | |
| 416.85K | $433.53K | 0.00% | Add | |
| 141.32K | $146.97K | 0.00% | New | |
| 141.32K | $146.97K | 0.00% | Reduce | |
| 64.92K | $67.52K | 0.00% | Hold | |
| 52.03K | $54.11K | 0.00% | Add | |
| 39.10K | $40.66K | 0.00% | Reduce | |
| 34.86K | $36.26K | 0.00% | Add | |
| 20.00K | $20.80K | 0.00% | Add | |
| 3.31K | $3.44K | 0.00% | Reduce | |
| 1.72K | $1.79K | 0.00% | Reduce | |
| 1.09K | $1.13K | 0.00% | Hold | |
| 468 | $487 | 0.00% | Hold | |
| 126 | $131 | 0.00% | New | |
| 2 | $2 | 0.00% | New |
Q1 2026 — 16 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 4.10M | $4.34M | 0.09% | New | |
| 382.47K | $405.42K | 0.00% | New | |
| 264.39K | $280.25K | 0.00% | New | |
| 157.49K | $166.93K | 0.00% | Add | |
| 64.92K | $68.82K | 0.00% | New | |
| 62.80K | $66.56K | 0.00% | Reduce | |
| 43.25K | $45.85K | 0.00% | Hold | |
| 39.89K | $42.28K | 0.00% | Add | |
| 19.62K | $20.80K | 0.00% | Hold | |
| 16.90K | $17.92K | 0.00% | New | |
| 15.08K | $15.98K | 0.00% | Add | |
| 6.60K | $7.00K | 0.00% | Hold | |
| 4.86K | $5.15K | 0.00% | New | |
| 1.09K | $1.15K | 0.00% | New | |
| 468 | $496 | 0.00% | New | |
| 1 | $1 | 0.00% | Reduce |
Q4 2025 — 15 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 448.76K | $700.07K | 0.00% | Add | |
| 122.47K | $191.05K | 0.00% | Add | |
| 109.81K | $171.30K | 0.00% | Add | |
| 64.39K | $100.45K | 0.00% | Add | |
| 56.24K | $87.73K | 0.00% | New | |
| 49.47K | $77.18K | 0.00% | Add | |
| 43.25K | $67.47K | 0.00% | Add | |
| 27.78K | $43.34K | 0.00% | New | |
| 26.47K | $41.29K | 0.00% | Add | |
| 19.62K | $30.61K | 0.00% | New | |
| 11.10K | $17.31K | 0.00% | New | |
| 10.44K | $16.29K | 0.00% | New | |
| 6.60K | $10.00K | 0.00% | New | |
| 3.19K | $4.97K | 0.00% | Reduce | |
| 10 | $16 | 0.00% | Add |
Q3 2025 — 11 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 419.71K | $499.46K | 0.00% | Add | |
| 101.49K | $120.77K | 0.00% | Reduce | |
| 50.12K | $59.65K | 0.00% | Hold | |
| 50.35K | $57.90K | 0.00% | Reduce | |
| 24.08K | $27.70K | 0.00% | Reduce | |
| 22.35K | $26.60K | 0.00% | Hold | |
| 10.37K | $12.34K | 0.00% | New | |
| 10.69K | $12.29K | 0.00% | New | |
| 4.01K | $4.62K | 0.00% | Reduce | |
| 2 | $2 | 0.00% | Reduce | |
| 1 | $1 | 0.00% | New |
Q2 2025 — 9 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 282.84K | $242.40K | 0.00% | Add | |
| 103.34K | $88.53K | 0.00% | Add | |
| 72.77K | $69.86K | 0.00% | Add | |
| 50.16K | $42.97K | 0.00% | Reduce | |
| 31.41K | $30.15K | 0.00% | Add | |
| 22.35K | $19.15K | 0.00% | Hold | |
| 17.27K | $14.00K | 0.00% | New | |
| 4.59K | $4.41K | 0.00% | Reduce | |
| 92 | $89 | 0.00% | Add |
New Positions (Q3 2026)
- Citadel Advisors 27.55K sh · $12.86K
- Citigroup Inc 5.91K sh · $2.76K
Fully Exited (vs previous quarter)
- GEODE CAPITAL MANAGEMENT, LLC sold 141.32K sh · $146.97K
- US BANCORP \DE\ sold 20.00K sh · $20.80K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 3.67M | 3.98M | 4.10M | — | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 416.85K | 416.85K | 382.47K | — | — | — | — | — | — | — | — | — |
| Geode Capital Management | 141.14K | 141.32K | 157.49K | 109.81K | 101.49K | 103.34K | 100.17K | 93.42K | 76.56K | 58.21K | 58.21K | 56.22K |
| VANGUARD FIDUCIARY TRUST CO | 94.40K | 64.92K | 64.92K | — | — | — | — | — | — | — | — | — |
| BlackRock Inc | 52.87K | 52.03K | 39.89K | 26.47K | 24.08K | 31.41K | 24.65K | 25.12K | 24.96K | — | — | — |
| STATE STREET CORP | 43.25K | — | 43.25K | 43.25K | 22.35K | 22.35K | 22.35K | 22.35K | — | — | — | — |
| Northern Trust Corp | 34.86K | 34.86K | 19.62K | 19.62K | — | — | — | — | — | — | — | — |
| Citadel Advisors | 27.55K | — | — | 64.39K | 50.12K | 50.16K | 91.60K | — | 14.53K | — | — | — |
| Renaissance Technologies | 14.70K | 39.10K | 62.80K | 122.47K | 10.69K | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 6.50K | 3.31K | 4.86K | — | 4.01K | 4.59K | 5.65K | 3.79K | 5.73K | 7.15K | 5.57K | 632 |
| Citigroup Inc | 5.91K | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 1.36K | 1.72K | 15.08K | 3.19K | 50.35K | 72.77K | 41.03K | 65.17K | 6.52K | — | — | 303 |
| TORONTO DOMINION BANK | 1.09K | 1.09K | 1.09K | — | — | — | — | — | — | — | — | — |
| WOLVERINE ASSET MANAGEMENT LLC | 468 | 468 | 468 | — | — | — | — | — | — | — | — | — |
| BARCLAYS PLC | 2 | 126 | — | — | — | — | — | — | — | — | — | — |
| Caitong International Asset Management Co., Ltd | 2 | 2 | — | — | — | — | — | — | — | — | — | — |
| Vanguard Group | — | — | — | 448.76K | 419.71K | 282.84K | 277.58K | 21.68K | 21.68K | — | — | — |
| Wells Fargo & Co | — | — | 264.39K | — | — | — | — | — | — | — | 74 | 73 |
| GEODE CAPITAL MANAGEMENT, LLC | — | 141.32K | — | — | — | — | — | — | — | — | — | — |
| Marshall Wace | — | — | — | 56.24K | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold ESLA?
As of 2026-Q3, 16 institutional funds reported holding ESLA (Estrella Immunopharma Inc Com) in SEC 13F filings, with a combined reported value of $2.11M.
How many shares of ESLA do institutions own?
13F filers reported 4.51M shares of ESLA, worth $2.11M in aggregate at the end of 2026-Q3.
Is institutional ownership of ESLA rising or falling?
Share counts moved -6.3% versus the prior quarter — distribution.
Who are the top institutional holders of ESLA?
The largest 13F holders are ARMISTICE CAPITAL, LLC, Vanguard Group, Wells Fargo & Co, VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of Estrella Immunopharma Inc Com?
The major shareholders of Estrella Immunopharma Inc Com (ESLA) by reported 13F value are ARMISTICE CAPITAL, LLC, Vanguard Group, Wells Fargo & Co, VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, among 32 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.